@FiercePharma: Japan reaping the benefits from faster approval process. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: ICYMI last week: FDA warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce
@CarlyHFierce: ICYMI last week: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce
> Eisai and Arena Pharmaceuticals ($ARNA) said the FDA accepted their application for approval of an extended-release version of their anti-obesity med Belviq. Release
> Johnson & Johnson ($JNJ) asked the FDA to approve expanded use of its anti-inflammatory drug Stelara, for patients with Crohn's Disease; the drug is already used to treat psoriasis and psoriatic arthritis. Release
> One analyst's survey found that 90% of industry respondents think Pfizer ($PFE) will hive off its established products unit after its proposed $160 billion megamerger with Allergan ($ACT). Report
Medical Device News
@FierceMedDev: From FierceDrugDelivery: Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article | Follow @FierceMedDev
@VarunSaxena2: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More from FierceDrugDelivery | Follow @VarunSaxena2
@EmilyWFierce: A behind-the-scenes look at Cards Against Biotechnology, Cubist's snarky 'last hurrah': FiercePharmaMarketing item | Follow @EmilyWFierce
> Nevro scores a victory in spinal cord stimulation patent battle with Boston Scientific. Article
> Q&A: Philips on what's next after the first year of HealthTech. Report
Biotech News
@FierceBiotech: Real R&D innovation demands that lines between academia and industry are blurred. Article | Follow @FierceBiotech
@JohnCFierce: Disgraced scientist's China venture resurrects fears of a human cloning comeback. Story | Follow @JohnCFierce
@DamianFierce: Actually, inversions are ... good? More from the NYT | Follow @DamianFierce
> Foundering Xoma flips its diabetes program to Novo Nordisk in a $295M deal. Report
> For real R&D innovation, blur the lines between pharma and academia: Panel. Editor's corner
> FDA to Repros: Wipe your PhIII drawing board clean and start over. More
> Puma preps its once-vaunted cancer drug for European submission. Article
Pharma Manufacturing News
> Xellia buys idled Bedford plant from Hikma, will hire 170. Report
> FDA warning letter blasts Dr. Reddy's for undisclosed testing. News
> Samsung BioLogics to build its third and largest plant in South Korea. Story
> Meda sells off Spain operation that makes Legalon API. Article
> GE investing $40M in Ireland plant and will add 140 jobs. Item
Pharma Asia News
> Pharmaceuticals in South Korea could drive economy's growth. Item
> Survey: Rates of HIV in Asia could reflect 'hidden epidemic.' More
> Israel's Teva and Takeda tie up for Japan generics business. Report
> Delhi court rules for Dr. Reddy's in Xarelto case. Story
> Russia hopes to lure drugmakers with increase in buying power. Article
Drug Delivery News
> Nature: Electronic on-demand delivery device is also bioresorbable. More
> Indian Institute of Science develops hep C delivery vehicle using siRNA. Story
> UCSD develops tech to isolate drug-delivery nanoparticles from the blood. Item
> Presage licenses cancer drug from India's Piramal to accelerate development using its microinjector. Report
> Impax earns permission to sell its FDA-approved modified-release Parkinson's med in Europe. Article
And Finally... Light therapy, often used to treat seasonal depression, may work for the non-seasonal kind, a study found. Report